Munich, September 7, 2020: inCare, today announced that it has appointed Dr. Erich Enghofer as a new member of its Scientific Advisory Board, reflecting the company’s focus on digital oncology therapeutics.
The Scientific Advisory Board represents a selection of scientific and pharma experts, who already contributed to the past digital health development and are from 2020 supporting inCare in the scientific and clinical development of its digital oncology programs.
Dr Erich Enghofer, Ph.D, is a former Executive VP Oncology/Hematology for 4SC AG, Bayer HealthCare Pharmaceuticals, MedacSchering Oncology and Amgen, respectively. He was for 10+ years Board Member of the German Cancer Society.
Erich Enghofer, Ph.D, is a former Executive VP Oncology/Hematology for 4SC AG, Bayer Heath Care Pharmaceuticals, Medac, Schering Oncology and Amgen, respectively. He was for 10+ years Board Member of the German Cancer Society. He will be supporting the existing board members Victor G. Villagra, M.D., FACP and Rainer Schandry, Ph.D.
Dr. Roman Schenk, inCare Chairman commented: “We are extremely proud that Erich Enghofer is joining our Scientific Advisory Board and will contribute with his excellent and long-lasting experience in oncology to our development programs in the oncology area.”
inCare is combining mobile applications, wearable and artificial intelligence technologies in a digital oncology medicine and therapy platform for everyone involved.
We are transforming cancer care by extending digital health and digital therapeutics beyond monitoring and offering deeper insights about patient health patterns, medication treatment effectiveness and side effects, leading to more informed healthcare decisions and better outcomes for everyone involved.
Media Contact: email@example.com